DrugEvidence

Rankings / Stopped for futility

Stopped for futility

Trials stopped in the last 90 days whose stated reason is a lack of effect or an interim analysis. The classification is rule-based and the original wording is shown next to it.

Last revised

Ranking

TrialSponsorPhaseReasonStopped
NCT06483789 HB BioTech, LLC PHASE2 Decision to terminate study due to a lack of efficacy in this study population. There were no safety concerns identified that contributed to this decision. 2026-09-09
NCT06079190 GlaxoSmithKline PHASE2 The study was terminated early due to meeting pre-specified efficacy futility criteria at planned interim analysis. 2026-08-18
NCT06029439 Neumora Therapeutics, Inc. PHASE3 NMRA-335140 did not achieve the primary endpoint across three randomized controlled trials. Program discontinued due to lack of efficacy in MDD. 2026-08-17
NCT05689021 Mayo Clinic PHASE2 Sponsor decided to close due to slow accrual and lack of efficacy 2026-07-02
NCT07006285 University Hospital, Strasbourg, France NA Because of the negative results reported in other studies 2026-06-30
NCT05018585 Diamyd Medical AB PHASE3 Stopped for futility. 2026-06-24